Figures computed from official regulatory filings — .
Analysttarget 11.14 USD (+88%) · consensus 5/5 · 5 buy · 0 hold · 0 sell
Ownershipinsiders 4.09% · institutions 45.08% · short 4.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Profound Medical Corp. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Menawat Arun Swarup | Buy | $43.3K | conv 63First in 12mo |
| SEC |
| Menawat Arun Swarup | Buy | $56.9K | conv 52 | SEC |